Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)
Latest Information Update: 13 Mar 2024
At a glance
- Drugs Afatinib (Primary) ; Docetaxel
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 21 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 21 Jul 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.